Beyond Air, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Beyond Air, Inc. on May 26, 2021. The report discloses the entry into a material definitive agreement regarding the Company's LungFit® PH product.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for a specific reporting period. The only financial figures disclosed relate to the terms of the settlement agreement:
- Refund Obligation: $10.5 million in upfront and milestone payments received in 2019.
- Refund Schedule: To be returned over a two-year period commencing after FDA approval of LungFit® PH.
- Future Royalty Cap: Circassia Group plc will receive royalties until aggregate payments reach $6.0 million.
Material Changes
The primary material change is the restructuring of commercial rights for LungFit® PH:
- Termination of License: Circassia Group plc, a former commercial licensee, has exited the arrangement.
- Global Rights: Beyond Air, Inc. now holds full global rights to LungFit® PH, including United States and China commercialization rights previously held by Circassia.
- Financial Reversal: The Company must return $10.5 million previously received, contingent on FDA approval.
Outlook, Risks, and Contingencies
Management Commentary and Terms:
- Contingent Liability: The obligation to return $10.5 million is triggered only after LungFit® PH receives United States Food and Drug Administration (FDA) approval.
- Future Royalties: Beginning in the third year post-approval, Circassia will receive a quarterly royalty of 5% of net sales in the United States, capped at $6.0 million in total.
- Documentation: The full text of the Settlement Agreement is expected to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2021.
Key Facts for Investor Verification
- Verify the current regulatory status of LungFit® PH with the FDA to assess the timing of the $10.5 million refund obligation.
- Review the upcoming Form 10-Q (Q2 2021) for the full text of the Settlement Agreement and any additional financial impacts.
- Confirm the Company's current cash position to evaluate its ability to fund the potential $10.5 million repayment upon FDA approval.
- Monitor future quarterly reports for the initiation of the 5% royalty payments to Circassia once sales commence.